Tamara Shushpanova | Drug Discovery and Development | Best Researcher Award

Prof Tamara Shushpanova,Tomsk National Research Medical Center of Russian Academy of Science, Russia

🧠 Tamara Vladimirovna Shushpanova – a leading researcher at the Tomsk National Research Medical Center of the Russian Academy of Sciences, specializes in neurochemistry and neuropharmacology 🧪. Her research focuses on the benzodiazepine receptor system in addiction, studying ligand binding in alcohol dependence using molecular docking with GABAA receptor sites. She has authored 100+ scientific papers, holds 5 patents, and has contributed to major conferences (EPA, WPA, ECNP) 📚. With extensive work on innovative molecules Halodif and Halonal, her contributions drive advancements in psychiatry, pharmacology, and addiction medicine. 🎓🔬

Publication Profile

orcid

Education

Prof. Tamara Shushpanova is a dedicated researcher at the Laboratory of Neurobiology, Russian Academy of Sciences 🧠. Her work spans Neurochemistry, Clinical Pharmacology, Psychiatry, and Addiction Medicine 🏥. She has contributed significantly to understanding ethanol’s effects on the human brain and targeted therapies for correction. Notable publications include Molecular-Cellular Targets of the Pathogenetic Action of Ethanol in the Human Brain in Ontogenesis, Halonal: An Original Benzoylated Phenobarbital Derivative Anticonvulsant, and A Novel Urea Derivative Anticonvulsant 📖. Through her research, she advances treatments for neurological disorders, enhancing clinical applications and therapeutic strategies 🔬.

Professional Memberships

Prof. Tamara Shushpanova is an active member of several prestigious professional organizations in neuroscience and psychiatry 🌍. She is affiliated with the European Psychiatric Association (EPA), the World Psychiatric Association (WPA), and the European College of Neuropsychopharmacology (ECNP) 🏥. These memberships connect her with leading experts, enabling collaboration on cutting-edge research in neurochemistry, clinical pharmacology, and addiction medicine 🔬. Through these associations, she contributes to global discussions on mental health, pharmacological advancements, and innovative therapeutic strategies 🧠. Her involvement ensures she remains at the forefront of scientific progress, shaping the future of psychiatry and neurobiology 📚.

Academic Research

Prof. Tamara Shushpanova actively shares her research on ResearchGate 📚, where her contributions to neurochemistry, clinical pharmacology, and psychiatry are accessible to the global scientific community 🌍. Her profile serves as a platform for collaboration, knowledge exchange, and engagement with fellow researchers 🔬. Additionally, she provides links to relevant identification and certification documents, ensuring transparency and credibility in her academic and professional endeavors 🏅. By maintaining an active digital presence, she enhances the visibility of her work, fostering innovation and scientific progress in the field of neuroscience and pharmacology 🧠

Research Focus

Tamara Shushpanova is a distinguished researcher specializing in neuropharmacology 🧠💊, medicinal chemistry ⚗️, and molecular neuroscience 🔬. Her work primarily focuses on the development of novel anticonvulsants, particularly targeting GABAA receptors for conditions like epilepsy and alcohol withdrawal syndrome. She explores drug delivery systems 🚀, enantiomeric drug behavior 🔄, and neuroimmune interactions 🧬. Her research spans molecular docking, chemometric analysis, and in vivo pharmacological studies, contributing to innovative treatments for neurological disorders. Additionally, she investigates prenatal alcohol exposure 🍷🚼 and its impact on brain development, emphasizing glioblasts and neuronal receptor formation in neuroimmune regulation.

Publication Top Notes

Halonal, an original benzoylated phenobarbital derivative anticonvulsant: in vivo evaluation, chemometric and molecular docking studies of enantiomers

Innovative Technology of the Self-Emulsifying Drug Delivery System of the Anticonvulsant Galodif

Synthesis and Properties of a Water-Soluble Ureide Derived from Gаlodif and Succinic Acid

A novel urea derivative anticonvulsant: In vivo biological evaluation, radioreceptor analysis of GABAA receptors and molecular docking studies of enantiomers

Effect of original anticonvulsant ortho-fluoro-benzonal on immune cells functional properties at chronic ethanol intoxication

The original anticonvulsant meta-Cl-benzhydrylurea (m-CL-BHM) induces of the liver monooxygenase system and stimulates the neuroimmune response in behavioral disorders of alcoholic origin

EMBRIOGENESIS OF NEURONAL ELENENTS (GLIOBLASTS AND GABAA RECEPTORS) IN THE HUMAN BRAIN NEUROIMMUNE SYSTEM UNDER PRENATAL ALCOHOL EXPOSURE

An Innovatory GABA Receptor Modulator and Liver Oxidase System Microsomal Cytochrome P450 Activator in Patients with Alcoholism

King Saud University, Saudi Arabia

Author Profile

🎓Early Academic Pursuits

Professor Ajaz Ahmad began his distinguished academic journey at the prestigious Hamdard University in New Delhi, India. He earned a Bachelor of Pharmacy (B.Pharm) in 2005, where he demonstrated an early inclination toward pharmaceutical sciences. Continuing his education at the same institution, he completed a Master of Pharmacy (M.Pharm) in 2007, refining his focus on drug delivery and molecular pharmacology. Driven by a passion for research, he pursued a Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences, which he completed in 2011. His doctoral research laid the foundation for his expertise in drug discovery, pharmacokinetics, and the molecular mechanisms underpinning drug actions.

💼Professional Endeavors

King Saud University, Saudi Arabia
Prof. Ahmad joined the College of Pharmacy at King Saud University in 2011 as an Assistant Professor in Clinical Pharmacy. Over the next decade, his contributions to research and teaching led to successive promotions—first as an Associate Professor in 2017 and then to his current role as Professor in Clinical Pharmacy in January 2024. At King Saud University, Prof. Ahmad’s role encompasses teaching advanced courses, mentoring postgraduate students, and conducting cutting-edge research in pharmacology and drug development.International Collaborations
Since 2015, Prof. Ahmad has served as a research collaborator with the Mayo Clinic, USA, a testament to his global reputation in pharmaceutical sciences. In 2013, he was appointed an Honorary Research Associate at the University of Hong Kong, further broadening his academic and professional network.Patents and Industry EngagementProf. Ahmad holds a U.S. patent (US20170231925A1) for treating neurovascular complications of diabetes mellitus. This innovation highlights his commitment to bridging the gap between research and practical healthcare applications.

🔬Contributions and Research Focus

Prof. Ahmad’s research covers a broad spectrum of topics in pharmaceutical sciences, with particular focus areas including:Preclinical Drug Development: He has explored novel therapeutic agents, focusing on their efficacy, safety, and molecular mechanisms.Pharmacokinetics and Drug Metabolism: His work delves into the ADME (absorption, distribution, metabolism, and excretion) properties of drugs, optimizing formulations and dosing regimens.Bioanalytical Method Development: Prof. Ahmad designs and validates analytical methods for drug quantification, ensuring reproducibility and precision.Animal Models for Disease Research: He conducts in vivo studies simulating human diseases like cancer, diabetes, and cardiovascular disorders, with a focus on ethical handling and translational applications.Sepsis Research: Investigating biomarkers for early diagnosis and developing therapeutic strategies to combat sepsis.Vascular Pharmacology: Using myography techniques, he explores interventions for vascular diseases and evaluates novel therapeutic targets.

📖Notable Publications

Molecular insights into anti-Protozoal action of natural compounds against

Authors : Raish M; Ahmad A; MOHD SHAHNAWAZ KHAN; Kalam MA
Journal: biomolecular structure & dynamics
Year: 2023

A BOX-BEHNKEN DESIGN FOR OPTIMIZATION OF ULTRASOUND-ASSISTED EXTRACTION OF SINAPIC ACID FROM FRAGARIA ANANASSA

Authors : Mudassar Shahid; Ahmad A; Raish M; Bin Jardan YA; Alkharfy KM; Ahad A; Abul Kalam M; Ahmad Ansari M; Iqbal M; Ali N et al.
Journal: Pharmaceutical Society
Year: 2023

Sinapic acid alleviates 5-fluorouracil-induced nephrotoxicity in rats via Nrf2/HO-1 signalling.

Authors : Ahmad Ansari M; Shahid M; Ahmad SF; Ahmad A; Alanazi A; Malik A; Bin Jardan YA; Attia SM; Bakheet SA; Raish M
Journal: Pharmaceutical Sciences
Year: 2023

A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment

Authors : Zhang, M., Si, S.J., Dai, W.J., … Jin, F., Jiang, L.Q.
Journal: Pharmaceutical Society
Year: 2023

Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism.

Authors : Mohammad raish; Ahmad A; Mudassar Shahid; Yousef A Bin Jardan; Abdul Ahad; Dr Mohd Abul Kalam; Mushtaq Ahmad Ansari; Muzaffar Iqbal; Ali N; Alkharfy KM et al.
Journal:Molecules
Year: 2023